V1 sact_regimen
730,471 rows · 12 columns
| MERGED_REGIMEN_ID | MERGED_TUMOUR_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | MERGED_PATIENT_ID | BENCHMARK_GROUP |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 240015838 | 240008450 | null | null | Palliative (P) | 2015-04-10 | 2015-07-04 | Cisplatin + Topotecan | N | N | 240035134 | IBRUTINIB |
| 240015839 | 240008466 | 1.79 | 108 | Not known (9) | 2013-01-11 | 2013-08-15 | Carboplatin + Etoposide IV 3 day | 02 | N | 240035318 | R IVAC |
| 240015840 | 240008471 | 1.77 | 71.2 | Adjuvant (A) | 2018-01-17 | 2018-01-18 | BENDAMUSTINE | N | N | 240035319 | CYCLOPHOSPHAMIDE + RITUXIMAB |
| 240015841 | 240008478 | 1.68 | 47.9 | Disease modification (D) | 2017-02-01 | 2017-05-19 | Cytarabine Low Dose | 02 | N | 240035325 | BENDAMUSTINE |
| 240015842 | 240008481 | 1.73 | 69.3 | Disease modification (D) | 2020-01-13 | 2020-01-14 | Chlorambucil | N | N | 240035348 | CHLORAMBUCIL |
| 240015843 | 240014437 | 1.73 | 82.5 | Disease modification (D) | 2015-06-16 | 2015-06-16 | IBRUTINIB | N | N | 240035356 | LEAM |
| 240015844 | 240008486 | 1.56 | 62.5 | Neo-adjuvant (N) | 2014-07-16 | 2014-07-16 | BEAM | N | null | 240035365 | IBRUTINIB |
| 240015845 | 240008490 | null | null | Palliative (P) | 2014-04-22 | 2014-05-20 | Bendamustine +/- Prednisolone | 2 | N | 240035436 | HYDROXYCARBAMIDE |
| 240015846 | 240008493 | 1.59 | 73.2 | Palliative (P) | 2014-06-02 | 2015-07-26 | LENALIDOMIDE | 02 | N | 240035442 | GEMCARBO |
| 240015847 | 240012542 | 1.71 | 45 | Adjuvant (A) | 2017-10-16 | 2017-11-19 | Gemcitabine + Oxaliplatin | N | N | 240035451 | PEMBROLIZUMAB |
| 240015848 | 240008496 | null | 90.8 | Not known (9) | 2018-06-14 | 2018-07-18 | AML17 TRIAL | null | null | 240035459 | CISPLATIN + GEMCITABINE |
| 240015849 | 240016144 | null | 84 | Palliative (P) | null | 2014-10-30 | BORTEZOMIB + RITUXIMAB | null | N | 240035460 | IVE-R |
| 240015850 | 240015400 | 1.66 | 55 | Palliative (P) | 2017-12-16 | 2017-12-19 | CAV | 2 | N | 240035509 | PEMBROLIZUMAB |
| 240015851 | 240008512 | 1.65 | 69 | Palliative (P) | null | 2015-11-01 | PEMBROLIZUMAB | 99 | N | 240035551 | IVE-R |
| 240015852 | 240008521 | 1.7 | null | Adjuvant (A) | 2015-07-08 | 2015-07-09 | IGEV R | N | null | 240035582 | R-GEM-P |
| 240015853 | 240012555 | 0 | 67 | Curative (C) | null | 2017-01-18 | RCEOP | null | N | 240035590 | DOXORUBICIN + OLARATUMAB |
| 240015854 | 240008530 | 1.61 | 75.7 | Disease modification (D) | 2016-01-28 | 2016-01-31 | OXALIPLATIN | 02 | N | 240000290 | VINORELBINE |
| 240015855 | 240008536 | 1.66 | 93 | null | 2016-06-19 | 2016-06-19 | Cytarabine HD + Methotrexate HD | 2 | N | 240000572 | CODOX M |
| 240015856 | 240008539 | 1.58 | 57.8 | Disease modification (D) | 2019-01-07 | 2019-03-15 | Cisplatin + Docetaxel +Fluorouracil | N | N | 240000791 | ICE-R |
| 240015857 | 240008549 | 1.65 | 55.4 | Curative (C) | 2015-05-01 | 2015-05-28 | Topotecan (intravenous) | N | N | 240001374 | ECX |
| 240015858 | 240008552 | 1.82 | 84 | Palliative (P) | 2016-07-23 | 2016-10-11 | ESHAP | 2 | N | 240001512 | GDP R |
| 240015859 | 240008555 | null | null | Curative (C) | 2017-01-14 | 2017-01-23 | Topotecan (intravenous) | 02 | N | 240001549 | IGEV R |
| 240015860 | 240008564 | 1.75 | 115 | Palliative (P) | 2016-08-07 | 2016-08-13 | UKALL14- Ph 1 Induction | 2 | N | 240002318 | AML17 TRIAL |
| 240015861 | 240008570 | 1.68 | 82.5 | Palliative (P) | 2015-01-08 | 2015-02-01 | Temozolomide 200mg/m2 | N | N | 240002486 | NAB-PACLITAXEL |
| 240015862 | 240012587 | 1.71 | 90 | Curative (C) | 2016-11-26 | 2016-11-29 | CYTARABINE + ETOPOSIDE | N | N | 240003250 | FLUOROURACIL + RT |
| 240015863 | 240012589 | 1.45 | 43.2 | Palliative (P) | 2014-04-27 | 2014-04-28 | VAC | 2 | N | 240003545 | BENDAMUSTINE + BORTEZOMIB |
| 240015864 | 240008596 | 1.57 | null | Disease modification (D) | 2018-03-01 | 2018-03-28 | R-GEM-P | N | N | 240004667 | ACE |
| 240015865 | 240012597 | 1.75 | 62.35 | Curative (C) | null | 2016-07-16 | CYTARABINE + METHOTREXATE + RITUXIMAB + THIOTEPA | N | N | 240004839 | FLAG |
| 240015866 | 240008601 | 1.59 | 93.12 | Palliative (P) | 2014-02-07 | 2014-02-20 | DOXORUBICIN | N | N | 240005033 | TOPOTECAN |
| 240015867 | 240008604 | 1.65 | null | Palliative (P) | 2014-07-17 | 2014-07-24 | VINCRISTINE | N | N | 240005082 | AML16 TRIAL |
| 240015868 | 240008609 | 1.68 | 58 | Palliative (P) | 2016-05-19 | 2016-05-20 | Docetaxel 75mg/m2 (21 day) | Y | N | 240005562 | IVAC |
| 240015869 | 240008636 | 1.58 | 92.6 | Palliative (P) | null | 2017-08-01 | IVAC | N | N | 240007399 | TOPOTECAN |
| 240015870 | 240008641 | null | 93.7 | null | 2016-06-07 | 2016-07-04 | Trifluridine + Tipiracil | null | null | 240007767 | BORTEZOMIB + RITUXIMAB |
| 240015871 | 240008643 | 0 | null | Curative (C) | 2016-12-11 | 2017-01-03 | GEM-P | N | N | 240007918 | FBC |
| 240015872 | 240008646 | 1.76 | 79.2 | null | 2019-03-01 | 2019-03-27 | Cytarabine intrathecal | Y | N | 240008056 | REMODL TRIAL |
| 240015873 | 240008651 | 1.84 | 93 | Palliative (P) | 2016-06-14 | 2016-12-20 | AML17 TRIAL | Y | null | 240008306 | ICE |
| 240015874 | 240008659 | 1.55 | null | Disease modification (D) | 2016-05-01 | 2016-05-06 | LENALIDOMIDE + RITUXIMAB | 02 | N | 240008463 | CVD |
| 240015875 | 240008663 | 1.78 | 63.7 | Curative (C) | 2015-01-26 | 2015-02-20 | IVE | N | N | 240008658 | CHOEP |
| 240015876 | 240008668 | 1.5 | 49 | Palliative (P) | 2014-08-29 | 2014-09-05 | CYTARABINE + METHOTREXATE + RITUXIMAB + THIOTEPA | 02 | N | 240008851 | CTD |
| 240015877 | 240012629 | 1.7 | 81 | Palliative (P) | 2016-09-24 | 2016-09-29 | PEMBROLIZUMAB | 02 | N | 240009295 | RCD TRIAL |
| 240015878 | 240008678 | 1.76 | 73.6 | Disease modification (D) | 2017-05-30 | 2017-09-05 | ETOPOSIDE + IFOSFAMIDE + RITUXIMAB | N | N | 240009614 | VINBLASTINE |
| 240015879 | 240008680 | 1.77 | 63.1 | Palliative (P) | 2017-04-23 | 2017-05-06 | Oxaliplatin + Modified de Gramont | N | N | 240009661 | DHAP - R |
| 240015880 | 240008685 | 1.63 | 55.4 | Curative (C) | 2016-07-20 | 2016-07-20 | CVP | N | N | 240009723 | LIPOSOMAL DOXORUBICIN |
| 240015881 | 240008689 | 1.67 | 59.3 | Palliative (P) | 2015-04-11 | 2015-09-03 | VINORELBINE | 02 | N | 240009989 | CAPECITABINE + GEMCITABINE |
| 240015882 | 240008694 | 1.58 | 53 | Curative (C) | 2018-04-10 | 2018-10-08 | CYTARABINE + METHOTREXATE | 02 | N | 240010103 | AML19 TRIAL |
| 240015883 | 240008696 | null | 68.2 | Curative (C) | 2018-12-03 | 2019-10-08 | Carboplatin + Topotecan | 02 | null | 240010391 | OFATUMUMAB |
| 240015884 | 240008702 | 1.45 | 89 | Palliative (P) | 2019-02-14 | 2019-02-15 | CAPECITABINE + GEMCITABINE | Y | N | 240010545 | CARBOPLATIN + RT |
| 240015885 | 240012651 | 1.66 | 0 | Not known (9) | 2018-12-04 | 2018-12-04 | UKALL14- Ph 1 Induction | N | N | 240011523 | GEMCITABINE + OXALIPLATIN |
| 240015886 | 240008715 | 1.67 | 49.4 | Adjuvant (A) | 2018-06-25 | 2018-06-26 | CISPLATIN + ETOPOSIDE + IFOSFAMIDE | 2 | N | 240011575 | CAPECITABINE |
| 240015887 | 240008721 | 1.85 | 58.5 | Disease modification (D) | 2016-11-25 | 2017-01-13 | CYTARABINE + METHOTREXATE + RITUXIMAB + THIOTEPA | N | N | 240011773 | CYTARABINE HD + METHOTREXATE HD |